Meet the Expert sessions are an opportunity for delegates to sit down and converse on a more one-to-one level with the experts in their field. They take place on the Monday, Tuesday and Wednesday of the meeting, from 08:00 - 09:00.
Please note that Meet the Expert sessions are not included in the general Meeting registration fee, and must be purchased separately. The fee is €30 (VAT included) per session. Tickets are available on a first-come, first-served basis.
For the first time this year, supporting companies provide additional Meet the Expert sessions over lunch on Monday and Tuesday. Pre-registration is required via the general registration form. For further information, please check our Industry Meet the Expert lunch sessions here.
Monday, August 31st
| CODE | TOPIC | EXPERT | ROOM |
|---|---|---|---|
| MTE-1 | Viral infections in HSCT recipients: the challenges in 2020 | Francisco Marty (US) | A10.01 |
| MTE-2 | Extracorporeal Photopheresis in the Management of Acute and Chronic GvHD | Daniel Couriel (US) | A10.05 |
| MTE-3 | The role of donor registries in the changing landscape of allogeneic HSCT in 2020 | Enric Carreras (SP) | A10.06 |
| MTE-4 | How to manage chronic GvHD in 2020 and beyond | Steven Pavletic (US) | A10.07 |
| MTE-5 | The role of cord blood banks in the changing landscape of allogeneic HSCT in 2020? | Sergi Querol (SP) | A10.12 |
| MTE-6 | How to establish a CAR T Cell Delivery Centre | Claire Roddie (UK) | A10.13 |
| MTE-7 | How to manage Acute Promyelocytic Leukemia in 2020. Current role of Hematopoietic Cell Transplantation | Miguel Ángel Sanz (SP) | A10.15 |
Tuesday, September 1st
| CODE | topic | expert | room |
|---|---|---|---|
| MTE-8 | HSCT in high-risk MDS | David Valcárcel (SP) | A10.01 |
| MTE-9 | Prophylaxis of acute graft versus host disease: ATG or not ATG? | Francesca Bonifazi (IT) | A10.05 |
| MTE-10 |
Clinical Hurdles for Academic Development of Clinical Advanced Therapies: the perspective from the GMP Lab |
Fermín Sánchez-Guijo (SP) | A10.06 |
| MTE-11 | The fast changing paradigm of myeloma treatment: what's best in 2020? | Sergio Giralt (US) | A10.07 |
| MTE-12 | How I manage double hit lymphomas | Andrew Davies (UK) | A10.12 |
| MTE-13 | The role of HSCT in Mantle Cell Lymphoma in 2020 | Olivier Hermine (FR) | A10.13 |
| MTE-14 | Maintenance strategies after allogeneic HSCT in patients with AML | Ali Bazarbachi (LB) | A10.15 |
Wednesday, September 2nd
| code | topic | expert | room |
|---|---|---|---|
| MTE-15 | Fungal infections in HSCT recipients - the challenges in 2020 | Livio Pagano (IT) | A10.01 |
| MTE-16 | HSCT and gene therapy in inherited metabolic diseases | Robert Wynn (UK) | A10.05 |
| MTE-17 | Current challenges facing emerging donor registries in 2020 | Mahmoud Aljurf (SA) | A10.06 |
| MTE-18 | HSCT indications in paediatric MDS | Charlotte Niemeyer (DE) | A10.07 |
| MTE-19 | Ex vivo cellular manipulation and therapy as the platform of choice for allogeneic HSCT in 2020 | Stephan Mielke (SE) | A10.12 |
| MTE-20 | Current role of mesenchymal stromal cells in HSCT | Peter Bader (DE) | A10.13 |
| MTE-21 |
HSCT in MS and immune-mediated neurological diseases: patient selection and follow-up |
Basil Sharrack (UK) | A10.15 |
Quality Management Meet the Expert Sessions
These sessions are free of charge and take place on the Tuesday of the meeting from 13:00 - 14:00. Pre-registration is required via the general registration form, under the Quality Management Group category.
Tuesday, September 1st
| CODE | TITLE | EXPERTS | ROOM |
|---|---|---|---|
| QM MTE 1 | Risk & Change Management | Dieter Klarmann (DE) Olga López Villar (SP) |
A10.05 |
| QM MTE 2 | Audits & Document development and control | Renza Monteleone (IT) Julie Dolva (NO) |
A10.06 |
| QM MTE 3 | Adverse events & CAPA | Anne Emmett (UK) | A10.07 |
| QM MTE 4 | Maintaining the QM program and QM plan | Nick van Sinderen (NL) Phuong Huynh (BE) |
A10.12 |
| QM MTE 5 | Outcome analysis and benchmarking & Validation and verification | Mara Magri (IT) Kim Orchard (UK) |
A10.13 |
| QM MTE 6 | Personnel, Training and Competency | Ilknur Kozanoglu (TR) Songül Tepebasi (TR) |
A10.15 |